COVID-19疫苗与血液学异常风险:巢式病例对照与自我对照病例系列研究
该研究利用香港医院管理局和卫生署数据,采用巢式病例对照与自我对照病例系列分析,评估CoronaVac和BNT162b2疫苗接种后血小板减少、白细胞减少和中性粒细胞减少的风险。共1 643 419人接种疫苗,仅观察到BNT162b2第二剂后白细胞减少风险增加(aOR 1.58,95%CI 1.24-2.02),CoronaVac无血液学异常风险增加,且疫苗后发生率远低于SARS-CoV-2感染后。
要点
- CoronaVac接种后未观察到任何血液学异常风险增加。
- BNT162b2第二剂后0-14天白细胞减少风险增加(aOR 1.58,95%CI 1.24-2.02)。
- 疫苗后血液学异常发生率远低于SARS-CoV-2感染后发生率。
核心结论
- 接种CoronaVac后未观察到血液学异常风险增加。
- BNT162b2第二剂后短期内观察到白细胞减少风险增加,但发生率远低于SARS-CoV-2感染后。
- COVID-19疫苗接种的获益仍大于血液学异常风险。
研究设计与样本
- 采用巢式病例对照与自我对照病例系列分析,数据来自香港医院管理局和卫生署。
- 共1 643 419人接种COVID-19疫苗,其中738 609人接种CoronaVac,904 810人接种BNT162b2。
- 感兴趣结局为血小板减少、白细胞减少和中性粒细胞减少。
- 使用条件logistic回归估计调整比值比(aOR)、发病率比(IRR)及95%置信区间(CI)。
主要发现
- CoronaVac接种后鉴定457例病例,BNT162b2接种后鉴定422例病例。
- CoronaVac接种后血小板减少、白细胞减少和中性粒细胞减少的发生率分别为每10 000剂2.51、1.08和0.15。
- BNT162b2接种后相应发生率分别为每10 000剂1.39、1.17和0.26。
- 每10 000例COVID-19病例中,血小板减少、白细胞减少和中性粒细胞减少的发生率分别为1254、2341和884。
- 仅观察到BNT162b2第二剂后白细胞减少风险增加(aOR 1.58,95%CI 1.24-2.02;第0-14天IRR 2.21,95%CI 1.59-3.08)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Several studies reported hematological abnormalities after vaccination against the coronavirus disease 2019 (COVID-19). We evaluated the association between COVID-19 vaccines (CoronaVac and BNT162b2) and hematological abnormalities. We conducted nested case-control and self-controlled case series analyses using the data from the Hong Kong Hospital Authority and the Department of Health, HKSAR. Outcomes of interest were thrombocytopenia, leukopenia, and neutropenia. Adjusted odds ratios (aORs), incidence rate ratios (IRRs), and 95% confidence intervals (CIs) were estimated using conditional logistic regression. In total, 1 643 419 people received COVID-19 vaccination (738 609 CoronaVac; 904 810 BNT162b2). We identified 457 and 422 cases after CoronaVac and BNT162b2 vaccination, respectively. For CoronaVac, the incidence of thrombocytopenia, leukopenia, and neutropenia was 2.51, 1.08, and 0.15 per 10 000 doses. For BNT162b2, the corresponding incidence was 1.39, 1.17, and 0.26 per 10 000 doses. The incidence per 10 000 COVID-19 cases were 1254, 2341, and 884, respectively. We only observed an increased risk of leukopenia following the second dose of BNT162b2 (aOR 1.58, 95% CI 1.24-2.02; day 0-14, IRR 2.21; 95% CI 1.59-3.08). There was no increased risk of any hematological abnormalities after CoronaVac vaccination. We observed an increased risk of leukopenia shortly after the second dose of BNT162b2. However, the incidence was much lower than the incidence following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. There was no association between CoronaVac and hematological abnormalities. The benefits of vaccination against COVID-19 still outweigh the risk of hematological abnormalities.
引用
- Sing CW, Tang CTL, Chui CSL, et al. COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study. Am J Hematol. 2022. PMID: 35080247. doi:10.1002/ajh.26478
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。